ProfileGDS5678 / 1457530_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 44% 43% 42% 43% 47% 43% 44% 55% 41% 43% 45% 42% 41% 43% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.0547144
GSM967853U87-EV human glioblastoma xenograft - Control 22.9957343
GSM967854U87-EV human glioblastoma xenograft - Control 32.9811842
GSM967855U87-EV human glioblastoma xenograft - Control 42.9428743
GSM967856U87-EV human glioblastoma xenograft - Control 53.0669147
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.090543
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.0969544
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.3618655
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.9262341
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.9833743
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.0461245
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.942742
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.9623941
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.9830743